Author: CannabisNewsWire (CNW)

About CannabisNewsWire CannabisNewsWire (CNW) is an information service that provides (1) access to our news aggregation and syndication servers, (2) CannabisNewsBreaks that summarize corporate news and information, (3) enhanced press release services, (4) social media distribution and optimization services, and (5) a full array of corporate communication solutions. As a multifaceted financial news and content distribution company with an extensive team of contributing journalists and writers, CNW is uniquely positioned to best serve private and public companies that desire to reach a wide audience of investors, consumers, journalists and the general public. CNW has an ever-growing distribution network of more than 5,000 key syndication outlets across the country. By cutting through the overload of information in today’s market, CNW brings its clients unparalleled visibility, recognition and brand awareness. CNW is where news, content and information converge. To receive SMS text alerts from CannabisNewsWire, text “CANNABIS” to 21000 (U.S. Mobile Phones Only) For more information please visit https://www.CannabisNewsWire.com Please see full terms of use and disclaimers on the CannabisNewsWire website applicable to all content provided by CNW, wherever published or re-published: http://CNW.fm/Disclaimer

Specialized Mortgage Loan Facilitator REZYFi, Inc. Represents Critical Capability for Hard-to-finance Cannabis Industry

  • Miami-based REZYFi Inc., is a mortgage lender that originates traditional loans but strategically is focused on non-traditional markets such as the cannabis industry
  • The cannabis industry has enjoyed a boom in market interest but still needs a reliable loan source for real estate mortgages
  • REZYFi’s strength as a commercial real estate lender is based on its licensing in the majority of states, with more to come, and in its proprietary automated / machine-learning technology
  • Improving national economy trends have reduced pressure on mortgage rates in recent weeks, and many analysts expect that mortgage rates will continue to decrease through the end of the year, increasing the number of loan-seekers in the process

Specialized mortgage loan originator REZYFi provides a critical service to the cannabis industry, which has exploded on the scene in recent years despite the hefty challenges involved in obtaining mortgage loans from federally insured banks reluctant to service an industry legalized only on a state-by-state level.

REZYFi’s model recognizes that income from licensed cannabis operators is legal and sustainable in states such as California, which boasts one of the largest economies in the whole world. The company provides senior loan and project financing optoins to state-licensed operators, with the loans secured by real estate and/or other assets of the borrowers “to the extent permitted by applicable laws and regulations governing such borrowers,” according to REZYFi’s website (https://cnw.fm/YqDr2).

The law of supply and demand means a high degree of competition for the limited properties that may be compliant with municipal regulations. This is key for marijuana businesses in an urban environment where the greatest number of customers are likely to be found. The report notes that the result can be a significant cost challenge for acquiring the real estate. Searching for properties that aren’t a top-grade quality, but which can be improved, or that are off-market in a “green zone” are among potential solutions to help alleviate that situation, it states. REZYFi is set up to deal with these issues.

REZYFi’s corporate strengths — including licensing in most states, with plans to become licensed in all remaining states in the near future, as well as proprietary automated / machine-learning technology that helps drive efficiency — helps clients in the cannabis industry find success. Reduced pressure on mortgage rates coinciding with cooling inflation trends has drawn many property buyers back into the market in recent weeks (https://cnw.fm/UR7i8).

For more information, visit the company’s website at www.REZYFi.com.

NOTE TO INVESTORS: The latest news and updates relating to REZYFi are available in the company’s newsroom at https://cnw.fm/REZY

About CannabisNewsWire

CannabisNewsWire (CNW) is an information service that provides (1) access to our news aggregation and syndication servers, (2) CannabisNewsBreaks that summarize corporate news and information, (3) enhanced press release services, (4) social media distribution and optimization services, and (5) a full array of corporate communication solutions. As a multifaceted financial news and content distribution company with an extensive team of contributing journalists and writers, CNW is uniquely positioned to best serve private and public companies that desire to reach a wide audience of investors, consumers, journalists and the general public. CNW has an ever-growing distribution network of more than 5,000 key syndication outlets across the country. By cutting through the overload of information in today’s market, CNW brings its clients unparalleled visibility, recognition and brand awareness. CNW is where news, content and information converge.

To receive instant SMS alerts, text CANNABIS to 21000 (U.S. Mobile Phones Only)

For more information please visit https://www.cannabisnewswire.com

Please see full terms of use and disclaimers on the CannabisNewsWire website applicable to all content provided by CNW, wherever published or re-published: http://CNW.fm/Disclaimer

Do you have questions or are you interested in working with CNW? Ask our Editor

CannabisNewsWire (CNW)
Denver, Colorado
www.cannabisnewswire.com
303.498.7722 Office
Editor@CannabisNewsWire.com

CannabisNewsWire is part of the InvestorBrandNetwork.

420 with CNW — Study Shows That Long-Term Use of Medical Cannabis Leads to Lower Opioid Dosages

A recent study published by the American Medical Association (AMA) found that patients with chronic pain who used medical cannabis for more than a month experienced a significant drop in the amount of opioids they were prescribed. The study, conducted by researchers at the New York Department of Health in collaboration with City University of New York and the Marijuana Management Office, examined 8,165 patients registered in the state’s medical cannabis program.

The researchers used data from the state’s medical marijuana programs from 2017 to 2019 to track how patients’ opioid prescriptions changed over time. The data included patients who had at least one opioid prescription and a recommendation for medical cannabis at the time they received their first marijuana prescription.

According to the findings, the number of opioids consumed by pain patients who received marijuana for more than 30 days was cut in half. Consequently, those who received marijuana for less than 30 days only experienced reductions of 4% to 14%.

The authors also noted that the rise in opioid-related casualties has resulted in stricter prescription guidelines, which has resulted in fewer opioid prescriptions and even a discontinuation by some patients. This abrupt disconnection puts patients who rely on opioids to manage their pain in a difficult situation. Some resort to the unregulated market, where risks such as fentanyl poisoning are much higher.

The new study was welcomed by cannabis supporters as additional proof that the substance can manage pain more effectively and safely than prescription medications. The findings, according to NORML, are in line with several other studies showing that patients often use cannabis to manage their pain and that many reduce or stop using opioids and other medications after receiving marijuana therapy.

James McDonald, New York’s acting commissioner of health, referred to the study as further proof that medical marijuana can reduce the quantity of opioid prescriptions required to treat severe pain.

Numerous anecdotal accounts, statistically significant studies and observational analyses have indicated that some people use cannabis as a substitute for conventional pharmaceutical drugs such as opioid painkillers and sedatives. The new study, however, adds to a growing body of literature that looks at cannabis as a potential treatment for chronic pain, particularly as an alternative to opioids.

Similar research revealed last month that legalizing cannabis for adult use at the state level was linked to reductions in opioid demand. According to the study’s findings, states with legal marijuana experienced a 26% decrease in the amount of pharmacy-prescribed codeine.

Furthermore, another AMA study revealed that two in six people with chronic pain report using marijuana as a form of treatment, and the majority of those people have done so in place of other painkillers such as opioids.

With such study results, it isn’t surprising that a number of enterprises such as India Globalization Capital Inc. (NYSE American: IGC) are looking to develop a range of THC-based treatments for various indications, such as chronic pain.

NOTE TO INVESTORS: The latest news and updates relating to India Globalization Capital Inc. (NYSE American: IGC) are available in the company’s newsroom at https://cnw.fm/IGC

About CNW420

CNW420 spotlights the latest developments in the rapidly evolving cannabis industry through the release of two informative articles each business day. Our concise, informative content serves as a gateway for investors interested in the legalized cannabis sector and provides updates on how regulatory developments may impact financial markets. Articles are released each business day at 4:20 a.m. and 4:20 p.m. Eastern – our tribute to the time synonymous with cannabis culture. If marijuana and the burgeoning industry surrounding it are on your radar, CNW420 is for you! Check back daily to stay up-to-date on the latest milestones in the fast -changing world of cannabis.

To receive instant SMS alerts, text CANNABIS to 21000 (U.S. Mobile Phones Only)

For more information please visit https://www.CNW420.com

Please see full terms of use and disclaimers on the CannabisNewsWire website applicable to all content provided by CNW420, wherever published or re-published: http://CNW.fm/Disclaimer

Do you have questions or are you interested in working with CNW420? Ask our Editor

CannabisNewsWire420
Denver, Colorado
http://www.CNW420.com
303.498.7722 Office
Editor@CannabisNewsWire.com

CNW420 is part of the InvestorBrandNetwork.

420 with CNW — Maryland Legislators Announce Proposed Law to Operationalize Voter-Approved Marijuana Legalization

Months after Maryland voters approved a ballot referendum to legalize marijuana, state legislators have unveiled a proposed bill to tax and regulate cannabis. Senators Brian Feldman and Antonio Hayes are sponsoring the Senate version of the bill while Delegates C.T. Wilson and Vanessa Atterbeary are carrying the House version.

With the law that legalized the possession of up to 1.5 ounces of cannabis for adults taking effect on July 1, 2023, the proposals are meant to prepare the state for regulating a commercial cannabis market. The proposals would levy a 6% tax for the first fiscal year beginning this summer before increasing the tax rate by 1% per year until it maxes out at 10% in 2028. Under the twin proposals, 30% of total tax revenue from cannabis would be directed to a community reinvestment fund for the next 10 years while 1.5% of tax revenue would be dedicated to localities while the Cannabis Business Assistance Fund and a Cannabis Public Health Fund would get 1.5% each.

The bills would also rename the Marijuana Alcohol and Tobacco Commission, making it the Maryland Alcohol, Tobacco and Cannabis Commission. The commission would be in charge of regulating the state’s cannabis program and would assist individuals who had been disproportionately affected by the war on drugs via an Office of Social Equity. The Office of Social Equity would partner with the Maryland Department of Commerce and the state comptroller to figure out the most efficient way to distribute cannabis tax dollars from the community reinvestment fund.

Furthermore, medical cannabis dispensary licenses would convert into dual licenses on July 1, 2023, when cannabis legalization takes effect if the license-holders have paid the required fee. After that, cannabis regulators would have until July 1, 2024, to start approving more recreational cannabis licenses.

According to Senate President Bill Ferguson, Maryland legislators have come up with a bill that has the potential of being the national model. Ferguson stated that the proposals would prioritize protecting public health while ensuring that individuals from communities that were disproportionately affected by cannabis criminalization have fair and equitable access to the cannabis industry. He also noted that the state must be ready to launch cannabis sales this July and craft smart rules to prevent ending up with more unlicensed shops, which has happened in other states.

A spokesperson from the governor’s office reported that the governor says the bills are “well-crafted” and he looks forward to working with the legislature.

When this legalization law takes effect, there may be cannabis companies that will need funding from sources such as REZYFi Inc. to keep their fledgling operations on the right footing as the market grows over the years.

NOTE TO INVESTORS: The latest news and updates relating to REZYFi, Inc. are available in the company’s newsroom at https://cnw.fm/REZY

About CNW420

CNW420 spotlights the latest developments in the rapidly evolving cannabis industry through the release of two informative articles each business day. Our concise, informative content serves as a gateway for investors interested in the legalized cannabis sector and provides updates on how regulatory developments may impact financial markets. Articles are released each business day at 4:20 a.m. and 4:20 p.m. Eastern – our tribute to the time synonymous with cannabis culture. If marijuana and the burgeoning industry surrounding it are on your radar, CNW420 is for you! Check back daily to stay up-to-date on the latest milestones in the fast -changing world of cannabis.

To receive instant SMS alerts, text CANNABIS to 21000 (U.S. Mobile Phones Only)

For more information please visit https://www.CNW420.com

Please see full terms of use and disclaimers on the CannabisNewsWire website applicable to all content provided by CNW420, wherever published or re-published: http://CNW.fm/Disclaimer

Do you have questions or are you interested in working with CNW420? Ask our Editor

CannabisNewsWire420
Denver, Colorado
http://www.CNW420.com
303.498.7722 Office
Editor@CannabisNewsWire.com

CNW420 is part of the InvestorBrandNetwork.

CannabisNewsBreaks – Lexaria Bioscience Corp.’s (NASDAQ: LEXX) DehydraTECH-CBD Demonstrates Higher Absorption at Lower Dose Levels

Lexaria Bioscience Corp. (NASDAQ: LEXX) recently announced it had demonstrated superior CBD blood absorption levels from its patented DehydraTECH(TM)-processed CBD compared to those of published comparators. “In their analysis, Lexaria’s researchers compared the average blood plasma levels of DehydraTECH-CBD at various dose levels (after the steady state or the amount of time needed before a consistent dose of drug achieves a stable plasma level had been reached) with that of non-Lexaria, pharmaceutical-grade CBD formulations published in two studies – a 2017 clinical trial and a 2019 study,” a recent article reads. “The 2017 trial evidenced an average blood plasma CBD level of 23.0 ng/ml after 22 days (the steady state) of daily dosing at a 5 mg/kg non-Lexaria CBD dose level. Lexaria’s HYPER-H21-4 study, on the other hand, showed that the DehydraTECH technology resulted in a 45.8% higher average blood plasma level (33.3 ng/mL) at DehydraTECH-CBD’s lowest dose level tested of just 3.38 mg/kg. When the dose level was increased to 4.46 mg/kg (the highest in the test), the blood plasma level was 133.4% higher than in the 2017 study at 53.7 ng/mL.”

To view the full article, visit https://cnw.fm/xW3o6

About Lexaria Bioscience Corp.

Lexaria’s patented drug delivery technology, DehydraTECH(TM), improves the way active pharmaceutical ingredients (“APIs”) enter the bloodstream by promoting more effective oral delivery. Since 2016, DehydraTECH has repeatedly demonstrated the ability to increase bio-absorption with cannabinoids, antiviral drugs, PDE5 inhibitors and more. DehydraTECH has also evidenced an ability to deliver some drugs more effectively across the blood brain barrier. Lexaria operates a licensed in-house research laboratory and holds a robust intellectual property portfolio with 28 patents granted and roughly 50 patents pending worldwide. For more information, visit the company’s website at www.LexariaBioscience.com.

NOTE TO INVESTORS: The latest news and updates relating to LEXX are available in the company’s newsroom at https://cnw.fm/LEXX

About CannabisNewsWire

CannabisNewsWire (CNW) is an information service that provides (1) access to our news aggregation and syndication servers, (2) CannabisNewsBreaks that summarize corporate news and information, (3) enhanced press release services, (4) social media distribution and optimization services, and (5) a full array of corporate communication solutions. As a multifaceted financial news and content distribution company with an extensive team of contributing journalists and writers, CNW is uniquely positioned to best serve private and public companies that desire to reach a wide audience of investors, consumers, journalists and the general public. CNW has an ever-growing distribution network of more than 5,000 key syndication outlets across the country. By cutting through the overload of information in today’s market, CNW brings its clients unparalleled visibility, recognition and brand awareness. CNW is where news, content and information converge.

To receive SMS text alerts from CannabisNewsWire, text “Cannabis” to 844-397-5787 (U.S. Mobile Phones Only)

For more information please visit https://www.cannabisnewswire.com

Please see full terms of use and disclaimers on the CannabisNewsWire website applicable to all content provided by CNW, wherever published or re-published: http://CNW.fm/Disclaimer

Do you have questions or are you interested in working with CNW? Ask our Editor

CannabisNewsWire (CNW)
Denver, Colorado
www.cannabisnewswire.com
303.498.7722 Office
Editor@CannabisNewsWire.com

CannabisNewsWire is part of the InvestorBrandNetwork.

Lexaria Bioscience Corp. (NASDAQ: LEXX) Expecting Additional Growth in 2023, Including IND Filing and IND Clinical Study

  • In addition to a recently released shareholder update letter from the company’s CEO, Chris Bunka, Lexaria Bioscience has now released a new investor presentation
  • Despite 2022 inflationary conditions, Lexaria has seen growth company-wide – including hitting annual budgets +/- 2% over the last two years
  • Lexaria’s patented DehydraTECH(TM) technology offers more effective delivery of active pharmaceutical ingredients into the bloodstream and brain tissue with 28 patents granted and roughly 50 patent applications pending worldwide
  • For Q1 2023, Lexaria expects additional results from its hypertension study HYPER-H21-4, dosing completion in its animal dementia study and diabetes study, dosing completion in human nicotine study NIC-H21-1, and submissions and publishing of additional results in research journals
  • Lexaria’s anticipated mid-year IND filing would be an important milestone for the company, providing additional interaction with the pharmaceutical industry

Lexaria Bioscience (NASDAQ: LEXX), a global innovator in drug delivery platforms, has released its new corporate presentation (https://ir.lexariabioscience.com/presentations). The presentation augments the positive outlook for the coming year put forth in an earlier released shareholder update letter from the company’s CEO, Chris Bunka.

Bunka starts the letter with, “As 2022 came to a close, it isn’t news that nearly all companies – not to mention most people – are facing challenges not experienced in years. Lexaria continues to navigate well and is focused on those things it can control, such as applied R&D designed to entice others to work with us commercially.” 

The letter (https://cnw.fm/NB167) shares that despite the some challenging conditions of 2022, Lexaria is forging ahead. It has not terminated staff but is experiencing the opposite, growing its external headcount to numbers higher than it has been in the past. This has allowed the company to conduct and analyze an unprecedented volume of work. Lexaria has managed to grow while exercising excellent fiscal controls, hitting annual budgets +/- 2% for the last two years. Lexaria plans for further growth in 2023 with its patented DehydraTECH(TM) technology.

DehydraTECH is a disruptive drug delivery technology that is more effective at delivering active pharmaceutical ingredients (“APIs”) into the bloodstream and brain tissue. It is applied to multiple ingestible product formats, including tablets, capsules, oral suspensions, mouth melts, and more.

The company has already seen 28 patents granted and roughly 50 patent applications pending worldwide for its DehydraTECH technology (https://cnw.fm/tyPjg). Pharmacokinetic studies have shown the delivery of higher API quantities in less time, including cannabidiol (“CBD”) for hypertension, oral nicotine for reduced risk, and antiviral drugs for COVID-19 and other infectious diseases. An Investigational New Drug (“IND”) enabling program is currently underway for DehydraTECH-CBD as a prospective registered treatment for hypertension with the U.S. Food and Drug Administration (“FDA”).

Pushing forward in 2023, Lexaria’s DehydraTECH drug delivery platform has multiple mainstream applications in cannabinoids, oral nicotine, antivirals, phosphodiesterase inhibitors, and other APIs. This technology increases bioavailability, improves the speed of onset, reduces drug administration costs, and masks unwanted tastes. The company’s pipeline addresses serious unmet patient needs with substantial market potential.

For Q1 2023, Lexaria expects additional results from its hypertension study HYPER-H21-4, dosing completion in its animal dementia study and diabetes study, dosing completion in human nicotine study NIC-H21-1, and submissions and publishing of additional results in research journals. Additionally, during 2023, Lexaria expects to both submit its IND file and commence its IND clinical study – a major step in its maturation as a pharmaceutical company and will be the primary research focus once it begins.

Lexaria believes that if the IND hypertension program is a success, it could potentially pave the way for more commercial pursuits of DehydraTECH-CBD for therapeutic use. This would be a real milestone for the company as an additional way to interact with the pharmaceutical industry.

For more information, visit the company’s website at www.LexariaBioscience.com.

NOTE TO INVESTORS: The latest news and updates relating to LEXX are available in the company’s newsroom at https://cnw.fm/LEXX

About CannabisNewsWire

CannabisNewsWire (CNW) is an information service that provides (1) access to our news aggregation and syndication servers, (2) CannabisNewsBreaks that summarize corporate news and information, (3) enhanced press release services, (4) social media distribution and optimization services, and (5) a full array of corporate communication solutions. As a multifaceted financial news and content distribution company with an extensive team of contributing journalists and writers, CNW is uniquely positioned to best serve private and public companies that desire to reach a wide audience of investors, consumers, journalists and the general public. CNW has an ever-growing distribution network of more than 5,000 key syndication outlets across the country. By cutting through the overload of information in today’s market, CNW brings its clients unparalleled visibility, recognition and brand awareness. CNW is where news, content and information converge.

To receive instant SMS alerts, text CANNABIS to 21000 (U.S. Mobile Phones Only)

For more information please visit https://www.cannabisnewswire.com

Please see full terms of use and disclaimers on the CannabisNewsWire website applicable to all content provided by CNW, wherever published or re-published: http://CNW.fm/Disclaimer

Do you have questions or are you interested in working with CNW? Ask our Editor

CannabisNewsWire (CNW)
Denver, Colorado
www.cannabisnewswire.com
303.498.7722 Office
Editor@CannabisNewsWire.com

CannabisNewsWire is part of the InvestorBrandNetwork.

420 with CNW — New Study Shows That Marijuana Legalization Hasn’t Worsened Drug Problem

Colorado is home to one of the largest legal cannabis markets in not just the United States but the entire globe. The industry has generated billions in tax dollars and employed tens of thousands of workers, after being launched barely more than a decade ago.

However, cannabis legalization in the state didn’t receive 100% support because some feared that legalizing the controversial plant would open up Colorado to criminal activity. In fact, most of the legalization campaigns around the country had to contend with claims that legalizing cannabis would lead to increased drug use among the youth and significantly increase criminal activity in the state.

Recent research now shows that most of these fears were unfounded and based on the misconception that cannabis was a gateway drug to other harder, life-threatening drugs such as heroin and cocaine. Researchers from the University of Colorado and the University of Minnesota built on research done last year which indicated that cannabis use among adults in Colorado increased after legalization.

However, the study failed to answer one crucial question: Has the increased cannabis use among Colorado adults led to negative outcomes?

Researcher Stephanie Zellers states that based on the findings of their recent study, the fact that adults in Colorado were consuming cannabis more frequently didn’t appear to have any negative outcomes from a “psychological point of view.” She and her colleagues leveraged long-term data collected from Colorado and Minnesota twins to assess the impact of marijuana legalization in Colorado and come to this conclusion.

They collected information about the twins’ behavior over a long time period; the information included marijuana us, and used in-built controls to account for variables such as genetic differences and socioeconomic status. Furthermore, the study also provided insight into how cannabis policy change in Colorado a decade ago affected people’s behavior because, unlike Colorado, Minnesota still hasn’t legalized cannabis.

The fact that the researchers used twins in the study also allowed them to eliminate possible variables such as family and cultural differences.

After analyzing data collected from more than 4,000 people, the research team found that legalization was not associated with an increase in cannabis-use disorder. Furthermore, Zellers added that the researchers did not notice any changes in tobacco and alcohol use or changes in personality, IQ or workplace among the study participants.

In their report, the researchers did note that participants who lived in states without recreational cannabis markets reported higher alcohol-use disorder rates and that participants were more likely to use alcohol in harmful or dangerous situations, such as before driving.

The study’s coauthor, CU psychology and neuroscience professor John Hewitt, concluded that the study showed that while no drug is risk free, the overt concern about regular recreational cannabis use in a legal market is unwarranted.

Regulated cannabis markets not only create opportunities for residents through cannabis companies but also through ancillary enterprises such as Advanced Container Technologies Inc (OTC: ACTX) that address the needs of marijuana companies.

NOTE TO INVESTORS: The latest news and updates relating to Advanced Container Technologies Inc. (OTC: ACTX) are available in the company’s newsroom at https://cnw.fm/ACTX

About CNW420

CNW420 spotlights the latest developments in the rapidly evolving cannabis industry through the release of two informative articles each business day. Our concise, informative content serves as a gateway for investors interested in the legalized cannabis sector and provides updates on how regulatory developments may impact financial markets. Articles are released each business day at 4:20 a.m. and 4:20 p.m. Eastern – our tribute to the time synonymous with cannabis culture. If marijuana and the burgeoning industry surrounding it are on your radar, CNW420 is for you! Check back daily to stay up-to-date on the latest milestones in the fast -changing world of cannabis.

To receive instant SMS alerts, text CANNABIS to 21000 (U.S. Mobile Phones Only)

For more information please visit https://www.CNW420.com

Please see full terms of use and disclaimers on the CannabisNewsWire website applicable to all content provided by CNW420, wherever published or re-published: http://CNW.fm/Disclaimer

Do you have questions or are you interested in working with CNW420? Ask our Editor

CannabisNewsWire420
Denver, Colorado
http://www.CNW420.com
303.498.7722 Office
Editor@CannabisNewsWire.com

CNW420 is part of the InvestorBrandNetwork.

420 with CNW — 2024 Adult-Use Marijuana Campaign Notches Major Victory in Florida

The possibility of legalizing recreational adult-use cannabis in Florida is becoming more visible. This is after a draft constitutional reform that might end recreational cannabis prohibition in Florida passed its initial procedural hurdle. However, before it is presented at the polls next year, it must meet two additional requirements.

For the legal and economic impact examination, the “Safe and Smart Florida” commission had to gather at least 222,899 verifiable voter signatures. Florida’s highest court — the Supreme Court — will review the suggested phrasing to make sure it isn’t misleading before it appears on the poll.

The potential impacts on the federal budget and any prospective modifications to other legislation will be examined by lawmakers and state officials in Florida. If everything goes according to plan, the group may need to collect 891,590 voter signatures in total to include the issue on the ballot.

To put it simply, this does not imply that the legislation will be adopted. Advocates and the electorate should work together to get the bill passed into law. For the proposal to pass, it must secure a minimum of 60% of the total votes cast in Florida. It is also difficult to gather 891,589 signatures, and this marks the beginning of the process to pass this measure.

By Feb. 2, 2023, the total number of acceptable signatures collected was 294,000, which was enough to have the measure analyzed.

Individuals older than 21 years of age would be legally able to possess, purchase, or use cannabis and other marijuana-related products for recreation in addition to medical use according to the draft bill.

Despite this, the proposed draft amendment bill clarifies that ending cannabis prohibition in Florida would not affect or insulate violations of federal rules but rather establish state-level limits for individual usage and propose a timetable for implementation. Florida has looked into legalizing the personal use of marijuana previously. The latest attempts to introduce that to the state legally failed in 2021 when a judge nullified the description of the amendment to appear in polls. The recent draft, which was filed in August 2022, might have a better reception with the backing of a well-known celebrity.

Currently, there are numerous restrictions on the lawful use of medicinal cannabis by residents of Florida. Although legalizing recreational cannabis in the state is still a long shot, its supporters are optimistic that, through a prominent celebrity endorsement, they can win over the people and get it passed.

While the push to end cannabis prohibition through voter initiatives and legislative means is ongoing, there are other companies such as India Globalization Capital Inc. (NYSE American: IGC) that are focused on developing therapeutic formulations from cannabinoids, which could gain FDA approval and find widespread use as regulated medicines.

NOTE TO INVESTORS: The latest news and updates relating to India Globalization Capital Inc. (NYSE American: IGC) are available in the company’s newsroom at https://cnw.fm/IGC

About CNW420

CNW420 spotlights the latest developments in the rapidly evolving cannabis industry through the release of two informative articles each business day. Our concise, informative content serves as a gateway for investors interested in the legalized cannabis sector and provides updates on how regulatory developments may impact financial markets. Articles are released each business day at 4:20 a.m. and 4:20 p.m. Eastern – our tribute to the time synonymous with cannabis culture. If marijuana and the burgeoning industry surrounding it are on your radar, CNW420 is for you! Check back daily to stay up-to-date on the latest milestones in the fast -changing world of cannabis.

To receive instant SMS alerts, text CANNABIS to 21000 (U.S. Mobile Phones Only)

For more information please visit https://www.CNW420.com

Please see full terms of use and disclaimers on the CannabisNewsWire website applicable to all content provided by CNW420, wherever published or re-published: http://CNW.fm/Disclaimer

Do you have questions or are you interested in working with CNW420? Ask our Editor

CannabisNewsWire420
Denver, Colorado
http://www.CNW420.com
303.498.7722 Office
Editor@CannabisNewsWire.com

CNW420 is part of the InvestorBrandNetwork.

REZYFi, Inc. Provides the Cannabis Industry with Critical Financing Options and Services Still Not Available with Traditional Banking Institutions

  • Cannabis businesses continue to face challenges finding opportunities for financing despite the continued drive for legalization
  • REZYFi is pivotal providing much-needed support to the cannabis industry through two wholly owned subsidiaries – REZYFi Lending and ResMac Inc.
  • For 2023, combined cannabis industry sales are projected to reach $38.8 billion

In recent years, the cannabis industry has seen significant changes – with 39 states legalizing cannabis for medicinal use and 21 states allowing recreational use. For 2023, the combined sales are projected to reach $38.8 billion for the industry (https://cnw.fm/LSWNV). In spite of this significant growth, there is a challenge that cannabis businesses face – access to loans, deposits, and credit cards. Even with Congress’ repeated attempts to pass banking and tax reform for the cannabis industry, there has not been a legislative consensus or enough political will to get it done.

Positioned as one of the first cannabis mortgage bankers in the United States, REZYFi is servicing the needs of both traditional and non-traditional consumers and businesses. The company targets markets that include licensed and permitted cannabis companies, owners of real estate who lease to cannabis companies, and companies and individual homeowners seeking a variety of real estate-related first and additional mortgage-based financing and project-specific financings. Headquartered in Miami, Florida, REZYFi operates through two wholly owned subsidiaries – REZYFi Lending and ResMac Inc.

Through REZYFi Lending, the company leverages a wide network to offer options such as 15- and 30-year fixed-rate loans, FHA loans, VA loans, reverse mortgages, jumbo loans, and adjustable-rate mortgages. REZYFi expects increased funding in marketing and loan agents to drive significant origination growth over the next two years, supported by its planned launch of a high-margin cannabis division.

REZYFi’s second wholly-owned subsidiary, ResMac, has been operating for 13 years. It has closed more than 20,000 loans for more than 15,000 clients. The company expects to accumulate $285 million in retail origination in 2023, alongside $250 million in wholesale origination for the same period. ResMac is further targeting $600 million in origination through its mortgage correspondent operations for 2023.

REZYFi’s diversified approach to the real estate lending sector positions it to capitalize on growth in multiple verticals. The global overall loan servicing market size was valued at $680.8 million in 2021. By 2028, the market is expected to reach $1426.6 million, growing at a CAGR of 11%, growth driven by a rise in demand for offering increased financing for mortgage lenders (https://cnw.fm/wVcSG).

Over the past five years, REZYFi has developed an extensive network of independent mortgage-related brokers and licensed loan officers and believes that this network will be a vital asset moving forward. Using its corporate strengths, REZYFi plans to expand its offering to all states and is currently licensed in 36 states. REZYFi plans to use its seasoned management team, which includes extensive experience in the cannabis and hemp marketplace.

For more information, visit the company’s website at www.REZYFi.com.

NOTE TO INVESTORS: The latest news and updates relating to REZYFi are available in the company’s newsroom at https://cnw.fm/REZY

About CannabisNewsWire

CannabisNewsWire (CNW) is an information service that provides (1) access to our news aggregation and syndication servers, (2) CannabisNewsBreaks that summarize corporate news and information, (3) enhanced press release services, (4) social media distribution and optimization services, and (5) a full array of corporate communication solutions. As a multifaceted financial news and content distribution company with an extensive team of contributing journalists and writers, CNW is uniquely positioned to best serve private and public companies that desire to reach a wide audience of investors, consumers, journalists and the general public. CNW has an ever-growing distribution network of more than 5,000 key syndication outlets across the country. By cutting through the overload of information in today’s market, CNW brings its clients unparalleled visibility, recognition and brand awareness. CNW is where news, content and information converge.

To receive instant SMS alerts, text CANNABIS to 21000 (U.S. Mobile Phones Only)

For more information please visit https://www.cannabisnewswire.com

Please see full terms of use and disclaimers on the CannabisNewsWire website applicable to all content provided by CNW, wherever published or re-published: http://CNW.fm/Disclaimer

Do you have questions or are you interested in working with CNW? Ask our Editor

CannabisNewsWire (CNW)
Denver, Colorado
www.cannabisnewswire.com
303.498.7722 Office
Editor@CannabisNewsWire.com

CannabisNewsWire is part of the InvestorBrandNetwork.

420 with CNW — Federal Data Shows Trucker Shortage Worsening Due to Marijuana Testing

Although dozens of states now allow the sale and consumption of either medical or recreational cannabis, federal law still outlaws the controversial drug. As a result, plenty of consumers have found themselves facing repercussions for consuming legal cannabis, especially employees in federal agencies and certain industries. According to recent data from the Department of Transportation (DOT), commercial truckers are the latest class of employees to be affected by cannabis testing requirements.

The Federal Motor Carrier Safety Administration reports that tens of thousands of truckers failed cannabis tests after federally mandated screenings. Many of them have refused to return to work, contributing to a massive labor shortage that has caused supply chain disruptions and increased inflation across the country.

Federal data shows that more than 100,000 truckers have tested positive for marijuana since 2020 and an estimated 166,000 people tested positive for some kind of controlled substance. Unsurprisingly, cannabis was the most-used drug, with most of those who failed the screening testing positive for marijuana. Additionally, nearly 41,000 truckers tested positive for cannabis last year.

Even though these truckers have a “return-to-work” option that would allow them to get their jobs back if they took another drug test, a significant portion of affected drivers haven’t taken the option. Data shows that around 91,000 of the overall 166,000 truckers who were affected by the screenings have not enrolled in the “return-to-work” process either. This has contributed to a labor shortage in one of the most critical industries in the country and is expected to have major economic consequences if it isn’t addressed quickly.

NORML Deputy Director Paul Armentano states that the DOT is partly to blame for the shortage of truckers due to its reliance on “discriminatory policies” and “outdated technology.” Armentano said in a recent blog post that workplace cannabis tests have never been an “evidence-based policy” but a discriminatory policy that bled over from the war on drugs of the 1980s.

He argued that times, attitudes and cannabis laws are changing across the country and that it is time for workplace policies to “adapt to this new reality” and stop punishing employees for engaging in legal activities outside of work hours.

Last year, Rep. Earl Blumenauer sent the head of the DOT a letter stating that the department’s drug testing policies were unnecessarily costing commercial truckers and drivers their jobs and contributing to the country’s ongoing supply chain issues.

Amid all this, many people are starting to grow their own cannabis in jurisdictions where that is allowed, and there is no shortage of people trying out novel indoor cultivation setups using the equipment made and marketed by enterprises such as Advanced Container Technologies Inc. (OTC: ACTX) in order to boost yields.

NOTE TO INVESTORS: The latest news and updates relating to Advanced Container Technologies Inc. (OTC: ACTX) are available in the company’s newsroom at https://cnw.fm/ACTX

About CNW420

CNW420 spotlights the latest developments in the rapidly evolving cannabis industry through the release of two informative articles each business day. Our concise, informative content serves as a gateway for investors interested in the legalized cannabis sector and provides updates on how regulatory developments may impact financial markets. Articles are released each business day at 4:20 a.m. and 4:20 p.m. Eastern – our tribute to the time synonymous with cannabis culture. If marijuana and the burgeoning industry surrounding it are on your radar, CNW420 is for you! Check back daily to stay up-to-date on the latest milestones in the fast -changing world of cannabis.

To receive instant SMS alerts, text CANNABIS to 21000 (U.S. Mobile Phones Only)

For more information please visit https://www.CNW420.com

Please see full terms of use and disclaimers on the CannabisNewsWire website applicable to all content provided by CNW420, wherever published or re-published: http://CNW.fm/Disclaimer

Do you have questions or are you interested in working with CNW420? Ask our Editor

CannabisNewsWire420
Denver, Colorado
http://www.CNW420.com
303.498.7722 Office
Editor@CannabisNewsWire.com

CNW420 is part of the InvestorBrandNetwork.

420 with CNW — AMA Study Concludes Cannabis Legalization Doesn’t Increase Psychosis Prevalence

A recent study published by the American Medical Association has revealed that there has been no notable increase in the number of diagnoses for psychosis in states where cannabis is legal compared to those where it is not. To investigate the possibility that cannabis legalization could be associated with higher rates of psychosis, which some prohibitionists have used as evidence against legalization, researchers at Pennsylvania University, Stanford University and the Department of Veterans Affairs examined data on more than 63 million beneficiaries of health insurance from 2003 to 2017.

The authors examined Medicare Advantage and commercial claims data in particular to evaluate the possible effects of cannabis legalization, which has been shown in some studies to increase adult usage rates. The researchers claim that the study was the largest and first to measure the relationship between the prevalence of health care related to psychosis claims throughout U.S. states and medical and recreational marijuana policies.

The findings, according to Deputy Director of NORML Paul Armentano, are “reassuring,” but he warned that it’s crucial to understand that some populations who are inclined to psychosis will likely be more susceptible than others to suffering negative effects from marijuana use. The study notes that it may be instructive to keep an eye on psychosis as a possible side effect of state-level marijuana legalization as more states introduce new policies.

While the notion of a connection between cannabis and psychosis is frequently raised in arguments made by proponents of prohibition against reform initiatives, writer Alex Berenson has established himself as one of the leading activists for the idea. His other assertions that cannabis use is linked to violent behavior were referenced in a 2019 study that was funded by the federal government, which found that legalization had a very minor effect on property crime violence.

Another recent government-funded study found that residents of states with legalized recreational marijuana have lower rates of alcohol use disorder than residents of states where marijuana is still illegal. In addition, another AMA study found that two in six people with chronic pain use cannabis as a pain relief option, with the majority of those people substituting cannabis for other painkillers such as opioids.

At the same time, another study published by the association concluded that legalizing medical cannabis at the state level is linked to a marked decline in prescription and opioid use among specific cancer patients.

With such results pointing to some of the implied benefits of legalizing cannabis, many more firms are likely to join the space and leverage the funding accessible through companies such as REZYFi Inc. in order to scale their operations and develop innovative offerings for customers.

NOTE TO INVESTORS: The latest news and updates relating to REZYFi Inc. are available in the company’s newsroom at https://cnw.fm/REZY

About CNW420

CNW420 spotlights the latest developments in the rapidly evolving cannabis industry through the release of two informative articles each business day. Our concise, informative content serves as a gateway for investors interested in the legalized cannabis sector and provides updates on how regulatory developments may impact financial markets. Articles are released each business day at 4:20 a.m. and 4:20 p.m. Eastern – our tribute to the time synonymous with cannabis culture. If marijuana and the burgeoning industry surrounding it are on your radar, CNW420 is for you! Check back daily to stay up-to-date on the latest milestones in the fast -changing world of cannabis.

To receive instant SMS alerts, text CANNABIS to 21000 (U.S. Mobile Phones Only)

For more information please visit https://www.CNW420.com

Please see full terms of use and disclaimers on the CannabisNewsWire website applicable to all content provided by CNW420, wherever published or re-published: http://CNW.fm/Disclaimer

Do you have questions or are you interested in working with CNW420? Ask our Editor

CannabisNewsWire420
Denver, Colorado
http://www.CNW420.com
303.498.7722 Office
Editor@CannabisNewsWire.com

CNW420 is part of the InvestorBrandNetwork.